RUTHERFORD, N.J.--(BUSINESS WIRE)--

Cancer Genetics, Inc. (CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based cancer diagnostics, will present at the second annual Marcum MicroCap Conference on Thursday, May 30, 2013 at 2:30 p.m. ET at the Grand Hyatt New York in New York City.

The Marcum MicroCap Conference is dedicated to introducing investors to the best undiscovered companies under $500 million in market capitalization. In addition, the conference will showcase a number of panels that discuss issues that are of vital importance to small cap issuers and investors. The conference is expected to draw more than 1,000 attendees, including senior personnel from over 100 presenting public companies, leading institutional investors, directors, bankers and service providers to the microcap marketplace.

To learn more about the Marcum MicroCap Conference, visit http://marcumllp.com/MicroCap.

About Cancer Genetics, Inc.

Cancer Genetics, Inc. (CGI) is an emerging leader in DNA-based cancer diagnostics and servicessome of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. CGI has established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic and the National Cancer Institute. For further information, please seewww.cancergenetics.com.

View original post here:
Cancer Genetics to Present at Marcum MicroCap Conference

Comments are closed.